The field of genetic evaluation has the potential to undergo a paradigm shift due to Next Generation Sequencing(NGS), also referred to as the next generation sequencing test. A significant advancement
GeneMind has raised nearly RMB 400 million in a Series C funding round, which it will put toward expanding the research and development of its products and applications, broadening the
On November 28, GeneMind officially launched the third self-developed sequencing system FASTASeq 300. GeneMind showcased the instrument at Medlab Middle East 2023, making its first worldwide debut at booth Z1.B39,
On March, GeneMind and Nanjing Jiangbei New District have reached a strategic partnership. The cooperation mainly focuses on promoting the industrialization and development of high-throughput sequencing technology. The two parties
GeneMind started its first exhibition journey in 2023 at Dubai World Trade Center for Medlab Middle East with its latest innovation from February 6 to 9. The show remains highly
